The TNF-Family Ligand TL1A and Its Receptor DR3 Promote T Cell–Mediated Allergic Immunopathology by Enhancing Differentiation and Pathogenicity of IL-9–Producing T Cells
Arianne C Richard,Cuiyan Tan,Eric T Hawley,Julio Gomez-Rodriguez,Ritobrata Goswami,Xiang-Ping Yang,Anthony C Cruz,Pallavi Penumetcha,Erika T Hayes,Martin Pelletier,Odile Gabay,Matthew Walsh,John R Ferdinand,Andrea Keane-Myers,Yongwon Choi,John J O'Shea,Aymen Al-Shamkhani,Mark H Kaplan,Igal Gery,Richard M Siegel,Françoise Meylan,Arianne C. Richard,Eric T. Hawley,Anthony C. Cruz,Erika T. Hayes,John R. Ferdinand,John J. O’Shea,Mark H. Kaplan,Richard M. Siegel
DOI: https://doi.org/10.4049/jimmunol.1401220
2015-03-18
The Journal of Immunology
Abstract:The TNF family cytokine TL1A (Tnfsf15) costimulates T cells and type 2 innate lymphocytes (ILC2) through its receptor DR3 (Tnfrsf25). DR3-deficient mice have reduced T cell accumulation at the site of inflammation and reduced ILC2-dependent immune responses in a number of models of autoimmune and allergic diseases. In allergic lung disease models, immunopathology and local Th2 and ILC2 accumulation is reduced in DR3-deficient mice despite normal systemic priming of Th2 responses and generation of T cells secreting IL-13 and IL-4, prompting the question of whether TL1A promotes the development of other T cell subsets that secrete cytokines to drive allergic disease. In this study, we find that TL1A potently promotes generation of murine T cells producing IL-9 (Th9) by signaling through DR3 in a cell-intrinsic manner. TL1A enhances Th9 differentiation through an IL-2 and STAT5-dependent mechanism, unlike the TNF-family member OX40, which promotes Th9 through IL-4 and STAT6. Th9 differentiated in the presence of TL1A are more pathogenic, and endogenous TL1A signaling through DR3 on T cells is required for maximal pathology and IL-9 production in allergic lung inflammation. Taken together, these data identify TL1A-DR3 interactions as a novel pathway that promotes Th9 differentiation and pathogenicity. TL1A may be a potential therapeutic target in diseases dependent on IL-9.
immunology